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Abstract: The purpose of the study was to assess the proportion of patients who achieve pain
relief thresholds, the time needed to reach the thresholds, and the relationship between pain
and inflammation among patients with rheumatoid arthritis (RA) and an inadequate response
to methotrexate in RA-BEAM (NCT0170358). A randomized, double-blind trial was conducted,
comparing baricitinib (N = 487), adalimumab (N = 330), and placebo (N = 488) plus methotrexate.
Pain was evaluated by patient’s assessment on a 0–100 mm visual analog scale (VAS). The following
were assessed through a 24-week placebo-controlled period: the proportion of patients who achieved
≥30%, ≥50%, and ≥70% pain relief, the time to achieve these pain relief thresholds, remaining pain
(VAS ≤ 10 mm, ≤20 mm, or ≤40 mm), and the relationship between inflammation markers and pain
relief. Baricitinib-treated patients were more likely (p < 0.05) to achieve ≥30%, ≥50%, and ≥70% pain
relief than placebo- and adalimumab-treated patients, as early as Week 1 vs. placebo and at Week 4
vs. adalimumab. A greater proportion of baricitinib-treated patients achieved ≤20 mm or ≤40 mm
remaining pain vs. placebo- and adalimumab-treated patients. Baricitinib-treated patients tended to
demonstrate consistent pain relief independent of levels of inflammation control. In RA patients with
an inadequate response to methotrexate, baricitinib provided greater and more rapid pain relief than
adalimumab and placebo. Analyses suggest the relationship between inflammation and pain may be
different for baricitinib and adalimumab treatments.
Keywords: baricitinib; disease-modifying antirheumatic drugs; pain perception; outcomes research;
patient perspective; rheumatoid arthritis
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1. Introduction
Rapid, sustained pain control is a foremost goal for many patients with rheumatoid arthritis (RA);
notably, in a survey approximately two-thirds of patients responded that pain was their treatment
priority [1]. Many patients with RA who have achieved control of inflammation associated with good
clinical response with RA therapy continue to report pain, including at levels described as moderate to
severe [1–4]. This remaining pain may be a result of the multifactorial nature of pain associated with
RA, which is not solely a result of inflammation; rather it may also be associated with structural damage,
peripheral sensitization, or central amplification [2,5,6]. For other patients, despite a treat-to-target
approach, the desired goal of remission cannot be attained. For these patients, ongoing pain is often a
predominant symptom.
In RA-BEAM, a Phase 3 clinical trial of baricitinib, an oral, selective inhibitor of Janus kinase (JAK)1
and JAK2, baricitinib plus methotrexate (MTX) was associated with significant clinical improvements
compared to patients treated with adalimumab plus MTX or placebo plus MTX. Baricitinib- and
adalimumab-treated patients demonstrated similar improvement in swollen joint count (SJC), with both
groups demonstrating significantly greater improvement relative to the placebo group beginning at
Week 1 that was maintained through the placebo-controlled period (Week 24). For patient-reported pain,
however, baricitinib-treated patients reported significantly greater improvements as early as Week 1
compared to placebo-treated patients, and as early as Week 2 when compared with adalimumab-treated
patients. These statistical differences in pain relief between the active treatment arms were maintained
through the duration of RA-BEAM (Week 52) [7]. This observation prompted us to explore differences
in pain relief with baricitinib- and adalimumab-treated patients in RA-BEAM.
Publications of clinical trials in RA traditionally evaluate pain improvement only as central
tendencies (i.e., mean change from baseline). To our knowledge, no prior reports have more fully
characterized treatment effects or explored the relationship between the control of pain and inflammation
with treatment. The objectives of this analysis were two-fold: first, to use the RA-BEAM data to assess
the proportion of patients who achieve pain relief thresholds and the time needed to achieve these
thresholds, and second, to investigate the relationship between inflammation and patient-reported pain.
2. Patients and Methods
2.1. Trial Design
The design and procedure of RA-BEAM have been described previously [7,8]. Briefly,
RA-BEAM was a randomized, double-blind, double-dummy, placebo-controlled and active-controlled,
parallel-arm, 52-week study conducted at 281 centers in 26 countries between 2012 and 2015
(ClinicalTrials.gov: NCT01710358). A total of 1305 patients on stable background MTX were randomly
allocated (3:2:3) to placebo, adalimumab 40 mg, or baricitinib 4 mg. At Week 16, those patients
considered non-responders received open-label rescue treatment with baricitinib 4 mg. After Week 16,
patients may have received rescue treatment at investigator discretion. At Week 24, placebo-treated
patients were switched to baricitinib. The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol
was approved by each center’s institutional review board or ethics committee. All patients provided
written informed consent.
2.2. Patients
Patients were ≥18 years old with active RA (≥6/68 tender and ≥6/66 swollen joints; serum
high-sensitivity C-reactive protein (CRP) ≥6 mg/L). Patients had an inadequate response to MTX and
either ≥3 joint erosions (based on radiographs), or ≥1 joint erosion with seropositivity for rheumatoid
factor or anti-citrullinated peptide antibodies [7].
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2.3. Pain Measures
Pain was measured with the patient’s assessment of pain visual analog scale (VAS), consisting
of one question, “How much pain are you currently having because of your rheumatoid arthritis?”
Responses range from 0 mm (no pain) to 100 mm (worst possible pain). The pain VAS was administered
at every study visit.
Pain Thresholds
Our initial observation of differential pain response between baricitinib and adalimumab was based
on mean change from baseline. We wanted to understand if these differences persisted when pain relief
was evaluated against various thresholds of success, as is typical for other patient-reported outcomes
in RA. Because there are no established, standard pain thresholds in RA, we reviewed the literature and
selected two approaches. First, we applied percent change from baseline threshold recommendations
from the general chronic pain literature, specifically those from the Initiative on Methods, Measurement,
and Pain Assessment in Clinical Trials (IMMPACT), a multidisciplinary organization with the mission
to develop consensus reviews and recommendations and to improve clinical trials of treatments for
pain [9,10]. A 30% improvement threshold is described as “much improved, meaningful differences”
and 50% represents “very much improved, substantial improvement” in chronic pain conditions.
A 70% improvement threshold, although not defined in IMMPACT, was also evaluated because it is
analogous to American College of Rheumatology response endpoints and was observed with patients
in RA-BEAM. Second, while relative improvement is important, so is absolute pain; thus we evaluated
thresholds of remaining pain (i.e., the absolute value of patient-reported pain) of ≤10 mm, ≤20 mm,
or ≤40 mm, at Week 24. The ≤10 mm threshold reflects limited pain to no pain and is extrapolated
from data by Wells et al. [11]. The ≤20 mm threshold represents a threshold when satisfaction with
health is not negatively affected by pain [11,12]. The ≤40 mm threshold was derived from observed
cut-off points between the pain VAS and the Patient Acceptable Symptom State (PASS) [13].
2.4. Outcomes
The proportion of patients achieving ≥30%, ≥50%, or ≥70% improvement from baseline by Week
24 was assessed, as was the median time when 50% of patients achieved these thresholds of pain relief.
The proportion of patients achieving remaining pain VAS values of ≤10 mm, ≤20 mm, or ≤40 mm was
assessed at Week 24. To evaluate if the differences in pain response were associated with inflammation,
we assessed the relationship between levels of inflammation and pain relief at Week 24.
2.5. Statistical Analyses
All analyses were conducted with an intention-to-treat approach in which data from patients who
received ≥1 dose of study drug were assessed, regardless of whether they completed the trial. Missing
values were imputed with modified last observation carried forward for all analyses where applicable.
Analyses were not adjusted for multiplicity.
Comparisons were made on the percent change in pain VAS from baseline to Week 24 using
analysis of covariance (ANCOVA) and on the proportion of patients achieving pain relief at Week 24
between treatment arms using logistic models, adjusted for randomization factors (region, baseline
joint erosion status (1–2 erosions plus seropositivity vs. ≥3 erosions)) and baseline pain VAS score.
The median time needed for patients to achieve these pain relief thresholds were assessed through
Week 24 using the cumulative incidence estimate with ‘competing risks’ which included rescue or
discontinuation due to lack of efficacy before reaching the pain relief threshold. The Cox proportional
hazards model with ‘competing risks’ (proportional sub-distribution hazards model) [14,15] was used
to obtain the hazard ratio.
Remaining pain was analyzed across treatment groups with logistic regression models. Pain relief
at Week 24 by CRP was evaluated using ANCOVA.
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A mediation analysis with multiple mediators was conducted to evaluate the relationship between
levels of inflammation and pain relief. The effects of change in inflammatory factors (CRP, erythrocyte
sedimentation rate (ESR), SJC) as multiple mediators on change in pain outcome for each treatment
over placebo during the 24-week period were evaluated in this analysis [16]. The total treatment effect
on pain relief over placebo that can be accounted for by changes in CRP, ESR, and SJC in the mediation
analysis is the ‘indirect’ or mediation effect, while the total treatment effect that cannot be accounted for
by the ‘indirect’ effect is called the ‘direct’ effect. Observed data were used for the mediation analysis.
Statistical analyses were performed in SAS (SAS Institute; Cary, NC, USA, version 9.4). A two-sided
p value < 0.05 was considered statistically significant.
3. Results
3.1. Pain Relief
As noted by Taylor et al. [7], patients had established and active RA. The mean baseline pain
scores were well matched across treatment groups in this study and ranged from 60 to 62 mm with the
median baseline pain of 62 mm [7]. Other baseline characteristics were well-balanced between the
treatment arms [7]. A detailed description of the safety of baricitinib and adalimumab is available in
the RA-BEAM publication [7]. In brief, adverse events were more frequent with baricitinib (71%) and
adalimumab (68%) than with placebo (60%) through Week 24. Rates of serious adverse events through
Week 24 were 5% with placebo, 5% with baricitinib, and 2% with adalimumab.
As early as Week 1, significantly greater improvement in pain relief was observed between
baricitinib and placebo (25% for baricitinib vs. 4% for placebo, p < 0.0001). At Week 24, the mean
percentage reduction in pain from baseline for baricitinib, adalimumab, and placebo, respectively,
were 51%, 39%, 17% (p = 0.001 for baricitinib and adalimumab vs. placebo and p = 0.030 for baricitinib
vs. adalimumab).
A greater proportion of patients treated with baricitinib or adalimumab achieved the ≥30%,
≥50%, or ≥70% pain relief thresholds compared with placebo-treated patients at Week 1 (Figure 1).
Compared with adalimumab-treated patients, a greater proportion (p < 0.05) of baricitinib-treated
patients achieved ≥30% and ≥50% pain relief as early as Week 4 and ≥70% pain relief at Week 8.
Differences between baricitinib and adalimumab for ≥50% and ≥70% pain relief were maintained
through Week 24 (Figure 1).
At Week 24, for the placebo-, adalimumab-, and baricitinib-treated patients, respectively, the
proportion of patients who achieved ≥30% pain relief were 49%, 69%, and 74%; for ≥50% pain relief,
the values were 32%, 52%, and 61%; and for ≥70% pain relief, the values were 16%, 32%, and 41%.
The median time to achieve the ≥30% pain relief threshold was 2 weeks for baricitinib- and
adalimumab-treated patients and 5 weeks for those on placebo (Figure 2). For ≥50% pain relief, the
median time was 4 weeks for baricitinib, 8 weeks for adalimumab, and 14 weeks for placebo (Figure 2).
For ≥70% pain relief, the median time was 12 weeks for baricitinib, 20 weeks for adalimumab, and
>24 weeks for placebo (Figure 2). Compared with placebo, baricitinib-treated patients were more
likely to achieve ≥30%, ≥50%, or ≥70% pain relief with Hazard Ratio (HR) values of 1.7, 1.9, and 2.5,
respectively (p ≤0.001). Compared with adalimumab, baricitinib-treated patients were more likely to
achieve ≥50% or ≥70% pain relief; the HR values for the ≥30%, ≥50%, or ≥70% pain relief thresholds,
respectively, were 1.1 (p = 0.145), 1.2 (p = 0.032), and 1.3 (p = 0.003).
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Figure 1. Percentage of patients who achieved pain relief thresholds from baseline, as measured by 
the pain VAS. *** p ≤ 0.001 vs. placebo; † p ≤ 0.05; †† p ≤ 0.01, ††† p ≤ 0.001 vs. adalimumab. 
Abbreviations: VAS = visual analog scale. Number of respondents who answered the pain question 
by week: placebo, n = 481 at Week 1 and n = 483 at all other weeks; adalimumab, n = 325 at Week 1 
and n = 327 at all other weeks; baricitinib, n = 482 at all weeks. 
Figure 1. Percentage of patients who achieved pain relief thresholds from baseline, as measured by the
pain VAS. *** p ≤ 0.001 vs. placebo; † p ≤ 0.05; †† p ≤ 0.01, ††† p ≤ 0.001 vs. adalimumab. Abbreviations:
VAS = visual analog scale. Number of respondents who answered the pain question by week: placebo,
n = 481 at Week 1 and n = 483 at all other weeks; adalimumab, n = 325 at Week 1 and n = 327 at all
other weeks; baricitinib, n = 482 at all weeks.
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Figure 2. Time course for patients attaining pain relief thresholds.  
3.2. Remaining Pain 
The differences in the proportion of patients who achieved the ≤40 mm, ≤20 mm, and ≤10 mm 
remaining pain thresholds were significantly greater for baricitinib and adalimumab compared with 
placebo as early as Week 1 (Table 1). Compared with adalimumab-treated patients, a greater 
Figure 2. Time course for patients attaining pain relief thresholds.
3.2. Remaining Pain
The differences in the proportion of patients who achieved the ≤40 mm, ≤20 mm, and ≤10 mm
remaining pain thresholds were significantly greater for baricitinib and adalimumab compared with
placebo as early as Week 1 (Table 1). Compared with adalimumab-treated patients, a greater proportion
of baricitinib-treated patients achieved the ≤40 mm threshold (p ≤ 0.001) at Week 4, and a difference
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was observed between the active treatment groups at the ≤20 mm threshold by Week 12 (p ≤ 0.001;
Table 1). Differences were maintained through Week 24. The percentage of patients who achieved
the ≤10 mm remaining pain threshold was greater for baricitinib compared to adalimumab, but the
difference reached statistical significance only at Week 12.
Table 1. Percentage of patients who met the thresholds of remaining pain (VAS) over time by treatment
groups. *** p ≤ 0.001 vs. placebo; † p ≤ 0.05; ††† p ≤ 0.001 vs. adalimumab.
Threshold of Remaining Pain
at Each Time Point (Week) Placebo n (%) Adalimumab n (%) Baricitinib n (%)
≤40 mm
1 150 (31) 132 (41) *** 208 (43) ***
4 193 (40) 169 (52) *** 298 (62) ***,†††
12 225 (46) 202 (62) *** 335 (69) ***,†
24 236 (49) 218 (66) *** 351 (73) ***,†
≤20 mm
1 51 (11) 64 (20) *** 90 (19) ***
4 80 (17) 93 (28) *** 158 (33) ***
12 103 (21) 120 (37) *** 209 (43) ***,†
24 105 (22) 121 (37) *** 239 (49) ***,†††
≤10 mm
1 20 (4) 32 (10) *** 40 (8) ***
4 29 (6) 49 (15) *** 88 (18) ***
12 52 (11) 63 (19) *** 124 (26) ***,†
24 56 (12) 86 (26) *** 144 (30) ***
3.3. Relationship between Inflammation and Pain Relief
At Week 24, among patients with varying levels of inflammation, as measured by CRP as
an objective marker of inflammation, baricitinib-treated patients tended to demonstrate consistent
pain relief regardless of the CRP levels. In contrast, patients treated with adalimumab and placebo
demonstrated less pain relief at higher CRP levels (Figure 3).
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vs. placebo; †† p ≤ 0.01 vs. adalimumab. Abbreviations: CRP = C-reactive protein.
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While the total effect of baricitinib on pain relief over placebo at Week 24 was greater than that for
adalimumab, changes in inflammation accounted for approximately 40% of the pain improvement
with baricitinib and 50% of pain improvement with adalimumab (Figure 4; Table S1). In this analysis,
the direct effects (i.e., those not associated with these markers of inflammation) of drug on pain relief
were higher for baricitinib than for adalimumab after accounting for indirect inflammatory effects
(Figure 4).
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4. Discussion
In the RA-BEAM trial, patient-reported improvements in disease activity, physical function, and
pain were greater for baricitinib plus MTX than for adalimumab plus MTX within 4 weeks of starting
treatment and were maintained throughout the 52-week observation period [7]. In this analysis, we
further explored pain relief experienced by patients. Baricitinib demonstrated greater and more rapid
achievement of clinically significant levels of pain relief than adalimumab or placebo through Week 24.
Furthermore, this differential effect became more marked as the pain relief thresholds increased, with
approximately 40% of the patients receiving baricitinib achieving ≥70% pain relief from baseline by
Week 24.
Another striking feature of this analysis was the rapid onset of effective mean pain relief at a
cohort level with baricitinib plus MTX. Here, we show that for those patients achieving ≥50% or ≥70%
pain relief, baricitinib had a shorter median time to achieving these pain relief thresholds than placebo
or adalimumab. Specifically, for ≥50% pain relief, the 4 weeks needed for baricitinib was approximately
half that of adalimumab treated patients (8 weeks). For patients achieving ≥30% pain relief, baricitinib
and adalimumab had similar median time to onset (approximately 2 weeks).
Remaining pain is commonly reported by patients with RA despite achieving satisfactory
disease control by adopting the treat-to-target approach in disease management. A threshold of
≤20 mm remaining pain is considered to represent a point where health satisfaction is not adversely
affected [11,12]. In our study, we found that patients treated with either baricitinib plus MTX or
adalimumab plus MTX were significantly more likely to achieve ≤10 mm, ≤20 mm, and ≤40 mm
thresholds for remaining pain compared to placebo plus MTX. Baricitinib separated from adalimumab
by Week 4 for the ≤40 mm and by Week 8 for the ≤20 mm threshold.
To explore the relative contribution of anti-inflammatory and other mechanisms of pain relief
obtained with either baricitinib or adalimumab, we explored relationships between changes in
patient-reported pain and an objective marker of inflammation, namely CRP. This analysis suggests
that the difference in pain relief between baricitinib and adalimumab cannot be solely accounted for by
differential effects on inflammation.
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While it is clear from multiple clinical studies that baricitinib has a profound anti-inflammatory
effect, as would be expected of a multi-cytokine inhibitor, these observations imply that JAK1 and
JAK2 inhibition also has anti-nociceptive effects that are independent of at least certain aspects of
the inflammatory process [17]. A rodent model indicated that treatment with baricitinib attenuates
complete Freund’s adjuvant-induced joint deficits, a surrogate measure of joint pain [18]. At present, the
mechanisms by which baricitinib modulates the pain experience independently of at least some generic
features of inflammation is unknown. One possible mechanism could involve granulocyte-macrophage
colony-stimulating factor (GM-CSF). GM-CSF is a cytokine that signals through JAK2 homodimers.
In a rodent collagenase-induced instability model of osteoarthritis, pain was shown to be GM-CSF
dependent, and therapeutic neutralization of GM-CSF rapidly and completely abolished arthritis
pain [19]. Another possible pathway is through phosphorylation of signal transducer and activator of
transcription 3 (STAT3). In rodent models of neuropathic pain following spinal nerve ligation, STAT3
phosphorylation was induced centrally in the dorsal spinal cord with upregulation of interleukin-6
(IL-6) mRNA in the dorsal root ganglia and elevated IL-6 concentrations in the dorsal spinal cord.
Intrathecal administration of a JAK2 inhibitor blocked this STAT3 phosphorylation pathway with
accompanying attenuation of both mechanical allodynia and thermal hyperalgesia [20]. It is known that
the JAK-STAT3 system is activated through IL-6 signaling in spinal microglia and that this transduction
pathway participates in development of pain associated with nerve alteration. However, it is not
known whether such mechanisms have relevance to pain in established RA.
In rodent arthritis models, autoantibodies to citrullinated proteins (ACPA) are reported to induce
joint pain independent of inflammation via a chemokine-dependent mechanism [21]. However, this is
unlikely to account for the differences in pain relief between TNF blockade and JAK inhibition in our
study as we did not observe statistically significant differences in ACPA change from baseline between
baricitinib and adalimumab at Week 24.
This analysis has limitations. Specifically, the present findings represent post hoc analyses in
which patients were not randomized according to their baseline pain. Pain studies may be complicated
by the subjective experience of pain and the inherent limitations of a VAS as an instrument to measure
pain experience. Additionally, the pain relief thresholds and remaining pain values are not yet firmly
established for RA [12,13]. Further, some concomitant medication use (e.g., glucocorticoids) are
controlled within a clinical trial, precluding assessment of any potential relationship between pain
improvement and medication changes.
Pain relief with treatment may have clinical and holistic implications. Patients who experience
pain relief are likely to report clinically significant improvements in other patient-reported outcomes,
such as the Patient’s Global Assessment of Disease Activity and functional disability [22,23]. More
broadly, reductions in pain have been associated with improvements in daily activity and work
productivity [24]. In this analysis, we have presented evidence that baricitinib rapidly provides pain
relief in patients with active RA on concomitant MTX to a magnitude greater than that observed with
the TNF inhibitor, adalimumab. We have expanded prior research through a new and detailed analysis
of the range of magnitude and kinetics of pain relief in a head-to-head study of baricitinib versus
adalimumab and by exploring the relationship between the control of pain and inflammation with
treatment. We observed that the inhibition of JAK1/JAK2 or TNF similarly ameliorate inflammatory
markers, but the overall pain and the non-inflammatory component are faster and more markedly
improved by baricitinib. Our findings merit further investigation into the biological mechanisms
underlying pain relief.
The observations from this analysis may be of importance in managing the unmet needs of
adequate pain relief in RA, whether in patients attaining the treatment targets of remission or low
disease activity or in those who are unable to achieve these targets with biologic anti-TNF treatment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/6/831/s1,
Table S1: Multiple mediator analysis coefficients for adalimumab vs. placebo and baricitinib vs. placebo at
Week 24.
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